FDA Clarifies Criteria for Accepting Reportable Manufacturing Changes For Biologics
Executive Summary
To reduce the number of unnecessary supplements being submitted to the agency, US FDA draft guidance clarifies which types of biologics manufacturing changes are considered minor and can be included in annual reports. The agency said that too many minor changes are being submitted as supplements.
You may also be interested in...
FDA Wants Risk Assessments To Support Post-Approval Changes For Biologicals
FDA has issued draft guidance calling for a risk management approach to assigning manufacturing change categories for licensed biological products. It updates a 20-year old version.
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.